PF-[ADDRESS_903961] Number: PF-[ADDRESS_903962] Name: [CONTACT_82111] (N/A)
[LOCATION_002] (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:N/A
Protocol Number: C1061011
Phase: 2a
Short Title : Phase 2a, 3-arm, 16-week, double-blind safety and pharmacodynamic study in 
adults with non-alcoholic fatty liver disease and type 2 diabetes mellitus
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in 
confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, [COMPANY_007] must be promptly notified.CCI
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 3Document History
Document Version Date Summary of Changes and Rationale
endpoints now includes modeling details: The 
derived endpoints will be anal yzed using 
MMRM with treatment, time and treatment b y 
time interaction as fixed effects and baseline 
value as a covariate.  Additional covariates, if 
considered for inclusion in the model, will be 
described in the SAP. 
Section 10.2. Appendix 2 (Clinical L aboratory  
Tests) will remove ALT and glucose as 
blinded parameters, as there is no significant 
risk of unintentional blinding based on these 
parameters. The previously  issued PACL  
described this change.
Section 10.4.1. Appendix 4 (Male Participant 
Reproductive Inclusion Criteria ) will be 
changed to state that, i n addition to male 
condom use, a highly  effective method of 
contraception is required (previousl y 
'considered') for WOCBP partners of male 
participants
.
Section 10.4.4. Appendix 4 (Contraception 
Methods) has been changed to remove 
reference to user depende ncy, and to no longer 
permit the following methods of contraception 
in potentially  child -bearing female partners of 
male participants: Progestogen onl y oral 
hormonal contraception where inhibition of 
ovulation is not the primary  mode of action; 
Male or fem ale co ndom with or without 
spermicide; Cervical cap, diaphr agm, or 
sponge with spermicide; 
A combination of 
male condom with either cervical cap, 
diaphragm, or sponge with spermicide (double 
barrier methods). These methods by  
[CONTACT_669291] y 
effective.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 4Document History
Document Version Date Summary of Changes and Rationale
Amendment 2 11 September 2019 Incorporation of results of C1061016 
midazolam drug -drug interaction study  to 
relevant background sections, and based on the 
results of this study , removal of relevant 
restrictions of CYP3A4 concomitant 
medications, given that clinical results indicate 
PF-06835919 does not induce 3A4 
metabolism. 
Specific changes are as follows:
2.2.1. (Nonclinical Overview) has now been 
revised to no longer indicate the potential for 
CYP3A4 induction with PF
-06835919.
2.2.2. (Clinical Overview) now makes 
reference to the C1061016 study , alongside 
other completed clinical studies.
2.2.3. (Preliminary  Pharmacokinetic Results of 
PF-06835919 -Midazolam Drug -Drug
Interaction Study  [C1061016]) has been added 
as a new subheadin g within the Clinical 
Overview, to provide a summary of the results 
of this study , including a stable on the effect of 
PF-06835919 on midazolam pharmacokinetic 
parameters. 
4.3. (Justification for Dose) now states that 
there is not expected to be an y effec t of 
PF-06835919 on the PK of CYP3A4 
substrates, and has removed reference to the 
former concomitant medication restrictions, 
accordingl y. 
6.5. (Concomitant Therapy ) has been updated 
to; remove the previous caution of potential 
altered exposure of lipid -modify ing agents that 
are 3A4 substrates; lift the restrictions on 
antihy pertensive agents that are significantly  
metabolized by  3A4; remove text in section on 
Other Prohibited Concomitant Medications 
which previousl y stated potential altered 
exposure of se nsitive 3A4 substrates.
PF-[ADDRESS_903963] OF FIGURES ...................................................................................................................9
1. PROTOCOL  SUMMARY ...................................................................................................10
1.1. Sy nopsis ..................................................................................................................10
1.2. Schema ....................................................................................................................10
1.3. Schedule of Activities ( SoA) ...................................................................................12
2. INTRODUCTION ...............................................................................................................14
2.1. Study  Rationale .......................................................................................................14
2.2. Background .............................................................................................................14
2.2.1. Nonclinical Overview .................................................................................15
2.2.2. Clinical Overview .......................................................................................16
2.2.3. Prel iminary  Pharmacokinetic Results of PF -
06835919- Midazolam 
Drug -Drug Interaction Study  (C1061016)
.......................................................17
2.3. Benefit/Risk Assessment
.........................................................................................18
3. OBJECTI VES, ESTIMA NDS, AND ENDPOINTS ................................ ........................... 19
4. STUDY DESIGN .................................................................................................................22
4.1. Overall Design .........................................................................................................22
4.2. Scientific Rationale for Study  Design .....................................................................22
4.3. Justification for Dose ..............................................................................................26
4.4. End of Study  Definition ..........................................................................................26
5. STUDY POPUL ATION
......................................................................................................27
5.1. I nclusion Criteria .....................................................................................................27
5.2. Exclusion Criteria ....................................................................................................28
5.3. L ifesty le Considerations ..........................................................................................32
5.3.1. Contraception ..............................................................................................32
5.3.2. Dietary  Restrictions ................................ ................................ .................... 32
5.3.3. Alcohol, Caffeine, and Tobacco ................................ ................................ .33
5.3.4. Activity .......................................................................................................33
5.3.5. Confinement to Site
....................................................................................33
5.3.6. Confinement at I maging Facility ................................................................33
5.4. Screen Failures ........................................................................................................34
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 66. STUDY INTERVENTIO N..................................................................................................34
6.1. Study  Intervention(s) Administered ........................................................................34
6.1.1. Administration ............................................................................................35
6.2. Preparation/Handling/Storage/Accountability ........................................................35
6.2.1. Preparation and Dispensing ........................................................................36
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................[ADDRESS_903964] .........................................................37
6.3.2. Bre aking the Blind ......................................................................................37
6.4. Study  Intervention Compliance ...............................................................................37
6.5. Concomitant Therapy ..............................................................................................38
6.5.1. Rescue Medicine .........................................................................................41
6.6. Dose Modification ...................................................................................................41
6.7. I ntervention After the End of the Study ..................................................................41
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................41
7.1. Discontinuation of Study  Intervention ....................................................................41
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_903965] to Follow -
up ....................................................................................................43
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................43
8.1. Efficacy  Assessments ..............................................................................................44
8.1.1. I maging Assessments ..................................................................................44
[IP_ADDRESS]. Assessment of L iver Fat and Stiffness Using FibroScan........44
[IP_ADDRESS]. Assessment of L iver Fat Using MRI -PDFF Acquisition 
and Anal ysis......................................................................................44
[IP_ADDRESS]. Analy sis of MRI -PDFF Images Including Determination 
of Eligibility .......................................................................................45
8.2. Safet y Assessments .................................................................................................46
8.2.1. Phy sical Examinations ................................................................................46
[IP_ADDRESS]. Measurement of Waist Circumference ......................................46
8.2.2. Bod y Weight ...............................................................................................47
8.2.3. Vital Signs ..................................................................................................47
8.2.4. Electrocardiograms
.....................................................................................48
8.2.5. Clinical L aboratory  Assessme nts...............................................................48
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Management of Glycemic Control............................................49
8.3. Adverse Events and Serious Adverse Events..........................................................52
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......52
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................53
8.3.2. Method of Detecting AEs and SAEs ..........................................................538.3.3. Follow-up of AEs and SAEs.......................................................................538.3.4. Regulatory Reporting Requirements for SAEs...........................................538.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational 
Exposure ..........................................................................................................54
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................54
8.3.6. Medication Errors .......................................................................................54
8.4. Treatment of Overdose............................................................................................558.5. Pharmacokinetics ....................................................................................................568.6. Pharmaco dynamics..................................................................................................57
8.6.1. Glucose, Insulin, and HbA1c......................................................................578.6.2. Lipid Panel..................................................................................................578.6.3. Urine for Albumin-to-Creatinine Ratio ......................................................578.6.4. hs-CRP........................................................................................................57
8.8. Biomarkers ..............................................................................................................58
8.8.1. Specified Gene Expression (RNA) Research .............................................588.8.2. Specified Protein Research .........................................................................588.8.3. Specified Metabolomic Research ...............................................................598.8.4. Banked Biospecimens for Biomarkers .......................................................59
8.9. Health Economics ...................................................................................................59
CCI
CCI
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 89. STATISTICAL C ONSIDERATIONS ................................................................................59
9.1. Estimands and Statistical Hypotheses .....................................................................59
9.1.1. Estimands....................................................................................................59
9.2. Sample Size Determination.....................................................................................619.3. Populations for Analysis .........................................................................................619.4. Statistical Analyses .................................................................................................62
9.4.1. Efficacy Analyses .......................................................................................629.4.2. Safety Analys es ..........................................................................................63
[IP_ADDRESS]. Electrocardiogram Analyses......................................................64
9.5. Interim Analyses .....................................................................................................64
9.5.1. Data Monitoring Committee.......................................................................64
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................66
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............66
10.1.1. Regulatory and Ethical Considerations ....................................................66
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................66
10.1.2. Financial Disclosure .................................................................................6710.1.3. Informed Consent Process ........................................................................6710.1.4. Data Protection .........................................................................................6810.1.5. Dissemination of Clinical Study Data ......................................................6810.1.6. Data Qu ality Ass urance ............................................................................70
10.1.7. Source Documents....................................................................................7110.1.8. Study and Site Closure..............................................................................71
10.1.9. Publication Policy.....................................................................................7210.1.10. Sponsor’s Qualified Medical Personnel .................................................72
10.2. Appendix 2: Clinical Laboratory Tests .................................................................7410.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................76
10.3.1. Definition of AE .......................................................................................76
10.3.2. Definition of SAE.....................................................................................77CCI
CCI
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 910.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.......................78
10.3.4. Reporting of SAEs....................................................................................81
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information ................................................................................................................83
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................8310.4.2. Female Participant Reproductive Inclusion Criteria.................................8310.4.3. Woman of Childbearing Potential ............................................................8310.4.4. Contraception Methods.............................................................................84
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments ........88
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................9010.8. Appendix 8: Abbreviations ...................................................................................[ADDRESS_903966] of PF-06835919 on Plasma 
Midazolam PK Parameters (AUC
inf, AUC lastand C max), Protocol 
C1061016..................................................................................................[ADDRESS_903967] OF FIGURES
Figure 1. Study C1061011 Design ...........................................................................11CCI
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 101.PROTOCOL SUMMARY 
1.1.Synopsis 
Since all sites conducting the study  will be located in North America , this is considered not 
applicable ( N/A).
1.2.Schema
The o verall study  design is captured below in Figure 1.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 142. INTRODUCTION
PF-06835919 is a ketohexokinase (KHK) inhibitor that is currently being investigated in 
participants with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH).
KHK is an enzyme catalyzing the conversion of fructose and adenosine triphosphate (ATP) 
to fructose-1-phosphate (F1P) and adenosine diphosphate (ADP), the first committed step in fructose metabolism.  In humans, Loss-of-function in KHK manifests as Essential Fructosuria, a rare, asymptomatic genetic condition
1that is only recognized by [CONTACT_669292].2,3PF-06835919 is a potent, 
reversible inhibitor of human KHK.  In nonclinical experiments, treatment with PF-06835919 reduces the incidence of fructose-induced hepatic steatosis and genetic deletion of KHK protects mice from fructose-induced hypertriglyceridemia, hyperinsulinemia, and hepatic steatosis (see investigators’ brochure [IB] Section 5). Based on initial experience in short duration clinical trials, inhibition of KHK appears generally safe and well tolerated. In addition, PF-06835919 treatment has shown the potential to reduce liver fat and biomarkers of inflammation (see Section 2.2.2 ).  It is anticipated that inhibition of KHK will decrease 
hepatic de novo lipogenesis and steatosis, thereby [CONTACT_669293].
2.1. Study Rationale 
The purpose of this study is to assess the safety and tolerability of PF-[ADDRESS_903968] of PF-06835919 treatment on liver fat, hemoglobin A1c (HbA1c), and additional pharmacodynamic (PD)/  parameters in participants with NAFLD and type 2 diabetes mellitus (T2DM).
2.2. Background 
Fructose metabolism, unlike glucose metabolism, is not subject to regulatory feedback 
inhibition in normal human biology.  As a consequence of unrestrained metabolism, fructose rapi[INVESTIGATOR_669274] a number of reactive and signaling metabolites that contribute to metabolic disease progression.  Along with the lack of feedback inhibition, hepatic fructose metabolism has been shown to reduce liver ATP concentrations after a single intravenous (IV) bolus of fructose.
4Depletion of ATP leads to the activation of adenosine monophosphate (AMP) 
deaminase5and subsequent increases in uric acid levels that have been shown to directly 
regulate hepatic lipogenesis through generation of mitochondrial oxidative stress.[ADDRESS_903969] demonstrated that fructose rapi[INVESTIGATOR_669275], leading to activation of the Carbohydrate Response Element Binding Protein (ChREBP), a highly lipogenic transcription factor, that can promote both steatosis and insulin resistance with carbohydrate over-feeding.
7Post-prandial hypertriglyceridemia is 
observed in both rodents and humans following fructose feeding, as fructose both decreases very low-density lipoprotein (VLDL) clearance and promotes de novo lipogenesis.
8CCI
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 15Excessive fructose consumption has been shown to cause features of metabolic sy ndrome 
and NAFLD.8In humans, s upplementation of a normal diet with 25% of the calories as 
fructose, but not as glucose, caused h yperlipi[INVESTIGATOR_669276] [ADDRESS_903970].9Increased sugar intake, in the form of carbonated beverages, 
has been associated with NAFLD in patients who lack other features of metabolic sy ndrome, 
suggesting that fructose intake independent of metabolic disease can increase liver fat.10,11In 
a separate stud y with participants consuming weight -neutral diets containing 25% of dietary  
calories as fructose, increased hepatic lipid and decreased hepatic insulin sensitivity  were 
observed after 9 days of high-fructose consumption.12Conversely , restricting dietary  sugar 
intake from 28% to 10% for 9 days improved insulin sensitivity  and reduced hepatic lipid in 
obese adolescents.13In a separate study , fructose at 5%, 8.75%, or 12.5% of the daily  caloric 
intake showed 
a dose-respons iveslight elevation in plasma trigl ycerides (TG) andelevation 
in uric acid.14In studies wi th matched calories provided as free glucose, fructose was unique 
in its ability  to promote insulin resistance, visceral obesity  and h yperlipi[INVESTIGATOR_035].[ADDRESS_903971] that the fructose, not gluc ose, component of dietary  sugar is 
unique in its ability  to promote features of metabolic sy ndrome, including steatosis, insulin 
resistance, and obesit y. 
NASH is a clinical and histological subset of NAFLD that is associated with increased
all-
cause morta lity, cirrhosis and end- stage liver disease, increased cardiovascular mortalit y, 
and increased incidence of both liver-related, and non -liver-related cancers.15Prevalence of 
NAFLD is estimated at 30 -40% of the US population, while prevalence of NASH is 
estimated at 3 -5% of the [LOCATION_002] ( US)population.15Risk factors for NASH include 
obesity , insulin resistance, T2DM, hy pertension, and dy slipi[INVESTIGATOR_035], as manifest ed by [CONTACT_669294] (HDL -C) and elevated TG s. 
There are no therapi[INVESTIGATOR_669277] y approved for the treatment of NASH, although a growing 
body  of evidence demonstrates the urgent need for such therapi[INVESTIGATOR_014].15NASH is diagnosed 
clinically  by [CONTACT_21731] y demonstrating steatosis, inflammation, and cy tological ballooning 
of hepatocy tes, often with vary ing degrees of fibrosis.  The clinical progression of NASH 
involves increasing degre es of fibrosis, with cirrhosis and/or hepatocellular carcinoma 
developi[INVESTIGATOR_10714] a subset of patients.[ADDRESS_903972] 
non-specific s ymptoms such as fatigue, despi[INVESTIGATOR_669278] .  More severe NASH is associated 
with elevated risk for progression to cirrhosis and 
liver-related mortality .
2.2.1. Nonc linical Overview
In exploratory  and/or pi[INVESTIGATOR_669279], testes and ovar y 
(rat), and the cardiovascular (rat, dog) and neuromuscular (dog) s ystems were identified as 
primary  targets. Adverse findings identified in the pi[INVESTIGATOR_669280] ≥100 mg/kg/day  
(no-observed-adverse- effect level [NOAEL ]= 30 mg/kg/day  in the 6 -month study , 2.8x the 
predicted human unbound area under the curve over 24 hours ( AUC 24) at the highest planned 
clinical dose of 300 mg once dail y [QD]), and an increased inci dence (relative to controls) of 
decreased/absent corpora lutea in the ovary  at ≥30 mg/kg/day  (NOAEL = 10 mg/kg/day  in 
PF-[ADDRESS_903973] planned clinical 
dose of 300 mg QD). The ovary  finding was not observed in shorter term toxicity  studies in 
rats at doses up to 175 mg/kg/day  for up to 6 weeks (up to 8.2x the predicted human unbound 
AUC 24at the highest planned clinical dose of 300 mg QD). Increases in heart rate and blood 
pressure were noted at ≥20mg/kg in safet y pharmacology and general toxicology  studies in 
dogs with a no-observed- effect level (NOEL) of 10 mg/kg and a margin of 1.5x the predicted 
human unbound maximum concentration ( Cmax) at the highest planned clinical dose of 
300mg QD. No PF -
06835919 -related arrh ythmia or structural injuries to the heart or blood 
vessels were observed in any  of the studies.
Tremors were noted in earlier exploratory  
toxicity  studies and in a single dog during the 6 -week pi[INVESTIGATOR_669281], ranging from 
being mild and self -terminating at 50 -60 mg/kg to being lasting and severe, with 
accompan ying clinical signs (eg, ataxia, panting, rapid breathing), at doses up to and 
including a non -tolerated dose of 300 mg/kg. Tremors were seen at exposures representing 
4.3-9.1x the predicted human unbound C max, but convulsions were not seen at equivalent 
exposures in any  study .PF-
06835919 had an ultraviolet (UV) light absorbance but was 
negative in the in vitro phototoxicity  assay , which indicates that it is not phototoxi c and no 
further photosafet y testing is recommended.
Although in vitro data indicated that PF-[ADDRESS_903974] planned clinical dose (300 mg QD) , based on clinical 
drug-drug interaction ( DDI) data (see Section 2.2.3 ), PF-[ADDRESS_903975] dose administered in this study  (300 mg QD) . In addition, 
PF-[ADDRESS_903976] that PF-06835919 has a low potential to inhibit intestinal P- glycoprotein 
(P-gp), breast cancer resistance protein ( BCRP ), OAT3, OATP1B1, and OATP1B3.   
The nonclinical safet y profile of PF -06835919 has been adequatel y characterized to support 
clinical trials of up to 16 weeks.
2.2.2. Clinical Overview
As of February  2019, there are3completed sponsor - initiated clinical trials that administered
PF-06835919 (C1061001, C1061002, and C1061003). Safet y and tolerabili ty findings from 
these 
studies are summarized below. In addition, a PF -06835919 midazolam DDI study  
(C1061016) is complete in the clinic and preliminary  results are provided below .
The safet y and tolerability of PF- 06835919 has been assessed in 2 Phase 1 s tudies in healthy  
adults, C1061001 and C1061002.  Across these 2studies, 78 healthy  adult participants (all 
males) were randomized, 68 (87%) were exposed to at least a single dose of PF -06835919, 
and 52 of these participants were exposed to repeated doses of PF -06835919.  Single oral 
doses (up to 600 mg) and repeated dail y doses (up to 330 mg) were found to be generally  
well tolerated with an acceptable safet y profile. There were no treatment -emergent adverse 
events (TEAEs) of ‘severe’ intensity in the Ph ase1 studies, andall of the TEAEs were ‘mild’ 
in intensity  except for 4 ‘moderate’ intensit y TEAEs (abdominal pain, ras h, and 
2participants with headaches ).  The most frequently  reported adverse event ( AE)following 
multiple dose administration of PF -06835919 in S tudy C1061002 washeadache (see 
IBSection 6.2).  
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 18Median plasma midazolam concentrations were similar following multiple doses of 
PF-06835919 compared to those observed for m idazolam administered alone.  Midazolam 
Tmaxvalues were similar between treatment periods (median T maxof 0.5 hours).  
Plasma 
concentrations declined in a monophasic manner with a similar mean terminal half- life (t 1/2) 
observed between the treatments: 5.267 hours for midazolam administered alone and 
4.986 hours when administered with multiple doses of PF-06835919.
T
he statistical comparison of plasma concentrations of midazolam administered alone and
with multiple dos
es of PF-06835919 are summarized in Table 1.The adjusted geometric 
mean for AUC inf and C max were similar, following co -administration with multiple doses of 
PF-
06835919 as compared to midazolam administratio n alone. The ratio of the adjusted 
geometric means of midazolam AUC inf, and C max(90% confidence interval [ CI]) were 
97.55% (79.91%, 119.08%) and 98.92% (76.44 %, 128.01%), respectively, following 
administration of midazolam with multiple doses of PF-06835919, relative to midaz olam 
administered alone.   Overall, these results indicate that there is no evidence of a meaningful 
effect 
of [ADDRESS_903977] of PF -06835919 on Plasma Midazolam PK 
Parameters (AUC inf, AUC lastand C max), Protocol C1061016
2.3.Benefit/Risk Assessment
In completed clinical studies, PF -[ADDRESS_903978] 
an acceptable safet y profile. There are no important identified risks for PF -06835919. The 
impo rtant potential risks for PF -06835919 identified in the nonclinical safety  studies include 
ovarian changes, cardiovascular effects, tremors, and spermatid degeneration. In the ovary , 
an increased incidence (relative to controls) of decreased/absent corpor a lutea was observed 
in female rats during the pi[INVESTIGATOR_22735] 6 -month GL P toxicity  study  at doses similar to the higher 
dose levels anticipated for use in human studies (see Section 2.2.1). This was con sidered 
adverse due to the potential negative effect on the animal’s fertility . However, these effects 
were not observed in rat studies up to [ADDRESS_903979] of PF -06835919 on 
female ovaries and fertility  is uncertain. As a precaution, women of child bearing potential 
(WOCBP) are excluded from this study .
Cardiovascular effects relate to an increase in heart rate seen at doses higher than those 
anticipate d for human studies, which were considered non -adverse with no other correlating 
ECG, clinical or anatomic pathology  findings, or impact to overall animal health. Tremors 
and spermatid degeneration were all observed at exposures higher than those tested i n 
clinical studies. No adverse cardiovascular effects or tremors have been observed in clinical 
studies to date. 
Based on S tudy C1061003, PF -[ADDRESS_903980] be en no significant adverse clinical 
trends in laboratory  values, vital signs, or changes in ECG parameters.  
The s ponsor considers that the available information about PF- 06835919 from the 
non-clinical and clinical studies completed to date provides a favo rable benefit -risk profile 
and supports the continued investigation of the compound as a potential treatment for NASH 
with liver fibrosis.
More detailed information about the known and expected benefits and risks ,and reasonabl y 
expected AEs
of PF-06835919 may be found in the IB, which is the single reference safet y 
document (SRSD) for this study .
3.OBJECTIVES , ESTIMANDS ,AND ENDPOINTS
Objectives Estimands Endpoints
Primary: Primary: Primary:
To evaluate the effect of 2 dose
levels of PF-06835919 compared
to placebo on whole liver fat
measured by [CONTACT_9268] -PDFF .
To evaluate the effects of 2 dose
levels of PF-06835919 compared 
to placebo on HbA1c .Estimand 1:
This estimand is intended 
to provide a population 
level estimate of the 
treatment effect of the IP 
alone relative to placebo 
under the scenario of no 
discontinuation of study 
intervention, without the 
potential confounding 
effects of additional 
prohibited medications, 
regardless of the 
participant’s compliance 
with the IP dosing.  
Details in Section 9.1.1 .%CFB in whole liver fat at 
16weeks using MRI -PDFF .
CFB in HbA1c at 16 w eeks.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 264.3.Justification for Dose
This study  is planned as a 3- arm, parallel group study  with 2 active PF -06835919 treatment 
arms (150 mg QD and 300 mg QD) and placebo to evaluate changes in liver fat and HbA1c
in participants with elevated liver fat and T2 DM. 
In Study C1061003 where PF - [ADDRESS_903981] been associated with a meaningful decrease in 
liver fat (approximate 20% reduction) while the lower dose of 75 mg was not significantl y 
different than placebo.  Both doses in C1061003 were generally  well tolerated.  The doses for 
this study  were selected in order to further evaluate the effects of 300 mg (in a different 
population and for a longer duration) and to determine if a dose between those studied in 
C1061003 would be associated with meaningful improvement in liver fat and/or other PD 
markers being evaluated in this study .  Notabl y, based on s ystems modeling based on data 
from the multiple ascending dose stud y in heal thy participants (C1061002), KHK inhibition 
in the liver at the 300 mg dose is expected to be near maximal.
With the exception of a decreased/absent corpus lutea finding in the 6 -month rat study  (note: 
women of child -bearing potential [ WOCBP] are excluded from this study ),anticipated 
unbound exposures of PF- 06835919 in this study  are expected to provide sufficient margins 
over findings in the 6 -month rat and 16- week dog toxicology  studies (see Section 2.2.1).  As 
exposures observed in the C1061002 study  were approximately  dose proportional, the 
anticipa ted exposure at the low dose (150 mg) is approximately  half that of the high dose.
It is anticipated that the [ADDRESS_903982] on OATP substrates, as the 280 mg dose administered in Part B of the 
C1061002 study  (see IB) which demonstrated an approximately  1.6-fold increase in 
atorvas tatin AUC .Based on preliminary  results of C1061016, P F-[ADDRESS_903983] dose in this study  (300 mg QD) has approximately  no meaningful effect on 
plasma concentrations of a co -administered sensitive 3A4 substrate (midazolam). Based on 
these results, CYP3A4 substrates are allowed in this s tudy. Specific concomitant medication
exclusions are detailed in Section 6.5.
In summary , the 300
mg QD dose selected forthis study  is intended to fully assess the 
potential for KHK inhibition to reduce liver fat and HbA1c in adults with NAFLD and 
T2DM .  The 150 mg dose was selected to explore if a dose between those that were 
previously  shown to be effective (300 mg) and not effective (75 mg) in lowering liver fat in a 
previous 6- week study  (C106 1003)  has potential for further clinical deve lopment.
4.4.End of Study Definition
A participant is considered to have completed the study  if he/she has completed all phases of 
the study  including the follow - up call (or visit, if required b y investigator) .
Theend of the stud y is defined as the date of the last visit 
or follow -up phone call of the last 
participant in the study .
PF-[ADDRESS_903984] y:
Age and Sex :
1.Male or female participants between the ages of 18 and 70 y ears, inclusive, at Visit 1 
(Screen 1).  Females must be of non- childbearing potential .
Refer to Appendix 4 for reproductive criteria f or male ( Section 10.4.1) and female 
(Section 10.4.2) participants.
Type of Participant and Disease Characteristics:
2.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
3.Participants with T2DM on stable doses (500 mg/day ) of metformin monotherapy  
for at least 
8weeks of Visit 1 (Sc reen 1).
4.At Visit 1 (Screen 1), waist circumference > 102 centimeters for males and 
>89centimeters for females with a maximum that allows for a subject to fit 
comfortabl y within the MRI machine.
5.At Visit 1 (Screen 1) and Visit 2 (Screen 2) , a CAPTM280 dB /m via FibroScan
assessment.
  If either CAPTMvalue is in the range of 260-279 dB/min, the 
measurement may  be repeated
,on a different day ,following at least a [ADDRESS_903985]
(except water) .
6.At Visit 3 (Screen 3), liver fat 8% measured by  [CONTACT_9268] -PDFF acquisit ion protocol at 
the 
sponsor -qualified i maging facility , confirmed via a single repeat, if deemed 
necessary  by [CONTACT_941] s ponsor -identified central imaging vendor (refer to Section 8.1.1).
7.HbA1c at Scree n 1(Visit 1), as assessed b y the sponsor -identified central laboratory  
of 7.0-10.5%, inclusive.  Repeat assessments of HbA1c to determine study  eligibility  
are NOT permitted.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 28Weight:
8.At Visit 1 (Screen 1), total body  weight of >50 kg (kilograms; 110lbs[pounds] ) and 
a BMI of 25.0 – 40.0 kg/m2, inclusive.
Informed Consent:
9.
Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions listed in the inform ed 
consent document (ICD ) and in this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Recent ( ie, within 6months prior to Screen 1) evidence or medical history  of unstable 
concurrent disease such as: clinically  significant hematological, endocrine, 
pulmonary , gastrointestinal (including severe gastroparesis), cardiovascular, hepatic, 
psychiatric, neurologic, or clinically  significant allergic disease (including drug 
allergies , but excluding treated and untreated seasonal allergies at the time of dosing).
2.History  or evidence of diabetic complications with significant end -organ damage, 
such as:
Proliferative retinopathy and/or macular edema; or diabetic neuropath y 
complicated b yneuropathic ulcers or judged to be clinically  significant as 
signified b y need for chronic pharmacological intervention ;
3.Other acute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) or active suicidal ideation or behavio r or laboratory  abnormality  that may  
increase the risk associated with study
 participation or IPadministration or may  
interfere with the interpretation of study  results and, in the judgment of the 
investigator, would make the participant inappropriate for entry  into this study .
4.Participants with any  of the following medical conditions: 
Any condition possibly  affecting drug absorption (eg, prior bariatric surgery , 
gastrectom y, ileal resection);
Diagnosis of t ype 1diabetes mellitus; 
Recent (ie, within the previous 6 months) history  of congestive heart failu re 
([LOCATION_001] Heart Association [NYHA] class III or IV) or unstable angina;
A history  of m yocardial infarction, stroke, or transient ischemic attack, within
6months of Screen 1 (Visit 1);
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 29Any malignancy  not considered cured (except basal cell carcinoma and squamous 
cell carcinoma of the skin); a subject is considered cured if there has been no 
evidence of cancer recurrence in the previous 5 years;
Active placement of medical devices in/on thoracic or abdo minal cavities such as 
pacemakers ordefibrillators.
5.Participants with any  anatomical or pathological abnormality  that would either 
preclude or tend to confound the anal ysis of study  data, including any  clinically  
significant abnormal findings on MRI obtai ned at Screen 3
(Visit 3), by [CONTACT_103] -
identified central imaging vendor, or participants meeting criteria for 
contraindication for MRI, including the following:
History  of severe claustrophobia impacting ability  to perform MRI during the 
study  despi[INVESTIGATOR_110244]/treatment with an anxioly tic;
Participants with metal implants, devices, paramagnetic objects contained within 
the body , and excessive or metal -containing tattoos;
Participants unable to lie still within the environment of the MRI scanner or 
maintain a breath hold for the required period to acquire images despi[INVESTIGATOR_310766]/treatment with an anxioly tic;
Participants with abdominal girth greater than the bore size of the site’s MRI  
system.
Prior/Concomitant Therapy:
6.Refer to Section 6.5 for details regarding prohibited prior/concomitant therapi[INVESTIGATOR_014] .
Prior/Concurrent Clinical Study Experience:
7.Previous administration with an investigational drug within 30 days (or as determined 
by [CONTACT_19970]) or [ADDRESS_903986] dose of IPused in this 
study  (whichever is longer). 
8.Participants with known prior participation in a trial involving PF-06835919 (ie, 
received at least 1 dose of IP).
Diagnostic Assessments:
9.Fasting 
plasma glucose levels >270 mg/dL (15.0 mmol/L) at the Screen 1 (Visit 1) or
run-in visit (Visit 4), as assessed by [CONTACT_456] -identified central laboratory and
confirmed b y a single repeat, if deemed necessary.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 3010. E vidence or diagnosis of other forms of chronic liver disease ,including but not 
limited to the entities listed below; evidence may  include laboratory  tests, as assessed 
by [CONTACT_941] s ponsor -identified central laboratory , with a single repeat at Visit 1(Screen 1)
permitted to assess eligibility , if neede d:
Hepatitis B virus (HBV), defined b y presence of hepatitis B surface antigen 
(HBsAg);
Hepatitis C virus (HCV), defined b y presence of hepatitis C antibody (HCVAb), 
andHCV ribonucleic acid (RNA , when reflexed based on a positive result for 
HCVAb);
Human Immunodeficiency Virus (HIV) infection, defined as presence of 
HIVantibody ;
Known diagnosis of p
rimary  biliary  cirrhosis, primary  sclerosing cholangitis, 
autoimmune hepatitis, or overlap s yndrome ;
History  of esophageal varices, ascites, or hepatic encepha lopathy ;
Alcoholic liver disease;
Wilson's disease, defined as ceruloplasmin level < lower limit of normal ( LLN );
Known diagnosis of hemochromatosis;
α-1-antitry psin (A1AT) deficiency , defined as A1AT level <LLN; 
Prior known drug -induced liver injury ;
Known or suspected 
hepatocellular carcinoma or other liver cancer;
History  of liver transplant, current placement on a liver transplant list, or current 
model of end- stage liver disease (MELD) score >12;
Histological presence of cirrhosis on prior biops y.
11. At Visit 1 ( Screen 1 ) , participants with an estimated glomerular filtration rate ( GFR )
<60 mL (milliliter) /min (minute) /1.73m 2as calculated b y the modif ication of diet in 
renal disease equation (MDRD), and confirmed via a single repeat, if deemed 
necessary . 
12.Participants with ANY of the following abnormalities in clinical laboratory  tests at 
Screen 1 (Visit 1) , as assessed b y the sponsor -identified centra l laboratory  and 
confirmed b y a single repeat, if deemed necessary: 
C
-peptide concentration <0.8 ng/mL (267 pmol/L [pi[INVESTIGATOR_669282]] );
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 31Fasting serum trigl ycerides 500mg/dL ( 5.65 mmol/L );
Fasting 
direct LDL -C >190 mg/dL (4.92 mmol/L) ;
AST or ALT  2.0x upper limit of normal (ULN);
Total bilirubin 1.5x ULN anddirect bilirubin ULN .
13.Seated sy stolic BP>160 mmHg and/or diastolic BP>[ADDRESS_903987] at Screen 1 (Visit 1).  BP isdetermined as the mean of triplicate 
measurements co
llected with [ADDRESS_903988] between measurements .
14. At Screen 1 (Visit 1), standard 12- lead ECG that demonstrates clinicall y relevant 
abnormalities that may  affect participant safet y or interpretation of stud y results (eg, 
baseline corrected QT [QTc F] interval >450 msec, complete left bundle branch block 
[LBBB], signs of an acute or indeterminate -age my ocardial infarction, ST -T interval 
changes suggestive of myocardial ischemia, second - orthird-degree atrioventricular 
[AV] block, or serious bradyarrh ythmias or tachy arrhy thmias).  If QTc Fexceeds 
450msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and 
the average of the 3 QTcFor QRS values should be used to determine the 
participant’s eligibility .  Computer -interpreted ECGs should 
be overread b y a 
physician experienced in reading ECGs before excluding participants.
15. A positive urine drug test for potential drugs of abuse at Screen 1 (Visit 1), including 
medical marijuana.  Participants that have been medicall y prescribed opi[INVESTIGATOR_858]/opio ids 
or benzodiazepi[INVESTIGATOR_669283] 1
(Visit 1) may be allowed to participate if approved by  [CONTACT_456].
Other Exclusions:
16. Compliance of <90% (based on pi[INVESTIGATOR_692]) during the 2- week, single -blind run-in 
period, as assessed prior to randomization on Day 1(ie, participants cannot miss more 
than 1 dose) .
17.History  (within the last 6 months) of regular alcohol consumption exceeding 
21drinks per week for men and 14
drinks a week for women (1drink = 5 ounces of
wine (150 mL) or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) .
18.Male participants with partners who are currentl y pregnant; or male participants able 
to father children and are unwilling or unable to use a highl y effective method of 
contraception for the duration of the study  and for at least 5days after the last dose of 
IP.
19. Participation in a formal weight loss program or use of agents suspected to cause
weight loss within 3 months prior to Visit 1 (Screen 1).
20. Weight loss of 5% within 1month prior to Visit 1 (Screen 1).
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 3221. Blood donation (excluding plasma donations) of approximately 1 pi[INVESTIGATOR_11731] (500 mL) or 
more within 56 days prior to randomization on Day 1 (Visit 6).
22. Investigator site staff members directly involved in the conduct of the study and their 
family members, site staff members otherwise supervised by [CONTACT_093], or [COMPANY_007] employees, including their family members, directly involved in the conduct of the study. 
5.3. Lifestyle Considerations
5.3.1. Contraception
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual participant and his partner(s) from the permitted list of contraception methods (see Appendix 4 Section 10.4.4 ) and will confirm that the participant has been instructed in its 
consistent and correct use.  At time points indicated in the SoA, the investigator or designee 
will inform the participant of the need to use highly effective contraception consistently and correctly and document the conversation and the participant’s affirmation in the participant’s chart (participants need to affirm their consistent and correct use of at least 1 of the selected methods of contraception).  In addition, the investigator or designee will instruct the participant to call immediately if the selected contraception method is discontinued or if pregnancy is known or suspected in the participant’s partner.
5.3.2. Dietary Restrictions
•Participants must abstain from all food and drink (except water) for ≥
≥8h o u r s prior to 
any blood sample collections for clinical laboratory tests, fasting glucose monitoring, 
•Water may be consumed as desired (ad libitum);
•Blinded IP must be administered every day with the morning meal;
•On scheduled outpatient visits to the site, in the morning , from Visit 4 (Day -14) 
through Visit 12 (Week 16), participants must be instructed to arrive without having 
morning meal/breakfast, self-administration of the blinded IP, andmorning dose of 
allowed concomitant medication(s), if applicable, for the given day;
•At Visit 4 (Day -14) through Visit 12 (Week 16), inclusive, the morning meal will 
be consumed with above-mentioned medications at the site [with the meal either
provided by [CONTACT_779], orthe participant provided a voucher (or similar) by [CONTACT_669295]].
•Each outpatient visit to the imaging facility (for MRI-PDFF) will occur following a 
fast (water permitted) of ≥4 hours; 
•For assessment via FibroScan®, visits will occur following a fast (water permitted) of 
≥4 hours;CCI
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 34Similar to MRI -PDFF, each assessment via FibroScantooccur at the same time 
of day  (2hours) relative to FibroScanassessment completed at 
Visit 1(Screen 1).
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to investigational product. A minimal set of screen 
failure information is required to ensure transparent reporting of screen failure participants to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements 
and to respond to queries from regulatory  authorities. Minimal information includes 
demograph y, screen failure details, elig ibility  criteria, and an y SAE .
Individuals who were considered screen failures may be rescreened only after a discussion 
with the sponsor . If rescreened, these participants should be assigned a different participant 
numbe r from the initial screening.
6.STUD Y INTERVENTION
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
For the purposes of this protocol, t he term IPmay be used s ynon ymously with study  
intervention.
6.1.Study Intervention(s) Administered
Intervention Name [INVESTIGATOR_16335]-06835919 Placebo for 
PF-06835919
ARM Nam e Active Placebo
Type Drug Drug
Dose Form ulation Tablet Tablet
Unit Dose Strength(s) Mg mg
Dosage Level(s) [ADDRESS_903989] ( IMP )
and Noninvestigational Medicinal Product 
(NIMP )IMP IMP 
Sourcing Provided centrally by [CONTACT_103] .
Refer to IP Manual for 
further information .Provided centrally by [CONTACT_103] .
Refer to IP Manual for 
further information .
Packaging and Labeling Study intervention will 
be provided in bottles.  
Each bottle w ill be 
labeled in blinded 
fashion as required per 
country requirement.Study interventi on will 
be provided in bottles.  
Each bottle w ill be 
labeled in blinded 
fashion as required per 
country requirement.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 356.1.1. Administration
Participants will swallow the IPwhole and will not manipulate or chew the IPprior to 
swallowing.
To maintain the blind, administration of I P will use a strategy  so that all participants will 
receive an equal number of tablets, regardless of which dose they  are assigned.  Tablets will 
be active drug ( 50mg or 100 mg) or placebo.
Participants will take a total of 3 tablets o f PF-06835919 and/or placebo at approximately  the 
same time each day and recommended to be taken with the morning meal.  
Dosing will be 
witnessed by  [CONTACT_669296] V isit 4, and Visits 6, 7, 8, 9,10, and 12.  Participants 
will be instructed to delay  self-administration of IP and concomitant medications on 
scheduled visit day s until they  arrive for their outpatient clinic visit, except participants in the 
sub-study  at their Week 14 (Visit 11).  At visits when participants report to the imaging
center, dosing and breakfast should be delay ed until completion of the MRI -PDFF procedure.
Participants should be instructed that if they  forget to take their morning dose at their usual 
time, they  should take the missed dose as soon as possible on the da y it was missed, however, 
there must be at least an 8 -hour interval between the missed dose and the next dose.  I f the 
participant remembers missing a dose the next day  or later, they  should be instructed NOT to 
take 2 doses in the same day . 
6.2.Preparation/H andling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervention , as 
applicable for temperature -monitored shipments . 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study 
intervention smust be stored in a s ecure, environmentally  controlled, and monitored 
(manual or automated recording ) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request.  Data for nonworking days must 
indicate the minimum and maximum temperature since previousl y documented for all 
site storage locations upon return to business.
3.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records). All study  
intervention swillbe accounted for using a nIP accountability form/record .  All empty  
containers should be returned to the site at each visit when drug accountability  will be 
performed .  
PF-[ADDRESS_903990] be quarantined and not used until [COMPANY_007] provides permission 
to use the study  intervention.  I t will not be considered a protocol deviation if [COMPANY_007] 
approves the use of the study  intervention after the temperature excursion. Use of the 
study  intervention prior to [COMPANY_007] approval will be considered a protocol deviation. 
Specific details regarding the definition of an excursion and information the site 
should report for each excursion will be provided to the site in the I P manual.
9.The sponsor or designee will provide guidance on the destruction of unused study  
intervention (eg, at the site).  If destruction is authorized to take place at the 
investigator site, the investigator must ensure that the materials are destro yed in 
compliance with applicable environmental regulations, institutional policy , and any  
special instructions provided by  [CONTACT_4618], and all destruction must be adequately  
documented.
Additional details about accountability , storage, destruction , and excursion reporting can be 
found in the I P manual.
6.2.1. Preparation and Dispensing
Participants will be assigned a subject identification number using an interactive response 
technology  (IRT)drug management s ystem.  The IPwill be dispensed using IRT at each visit 
from Visit 4(single -blind) to Visit 
10(double -blind) , exclud ing Visit s 5 and 1 1 ( Note: 
Visit 11 applicable only to participants in the substudy ).  A qualified staff member will 
dispense the IPvia unique container numbers in the bottles provided, in quantities 
appropriate for the stud y visit schedule.  The particip antshould be instructed to maintain the 
product in the bottle s provided throughout the course of dosing and return the bottle s to the 
site at the next study  visit.   Dosing instructions will be provided to the sites and individual 
participants.  Upon recei pt of the new bottle, the used bottle will be returned.  Participants
will be instructed to store the study  drug at room temperature and out of the reach of small 
children.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 376.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Investigational Product
Allocation of participants to treatment groups will proceed through the use of an IRT system.  
The site personnel (stud y coordinator or specified designee) will be required to enter or select 
information including but not limited to the user’s ide ntification (ID) and password, the 
protocol number, and the participant number.  The site personnel will then be provided with a 
treatment assignment, randomization number, and dispensable unit (DU) or container number 
when IPis being supplied via the I RTsystem.  The I RT s ystem will provide a confirmation 
report containing the participant number, randomization number, and DU or container 
number assigned.  The confirmation report must be stored in the site’s files. 
IPwill be dispensed at the study  visits summarized in the SoA . 
Returned IPmust not be redispensed to the participants.
The study -specific I RT reference manual and I P manual will provide the contact [CONTACT_19974] s ystem.
6.3.2. Breaking the Blind 
The I RT will be programmed with blind -breaking instructions. In case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’s 
treatment assignment is warranted. Participant safety  must alw ays be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every  effort to contact [CONTACT_1152] a 
participant’s treatment assignment unless this could delay  further management of the 
participant. If a participant’s treatment assignment is unblinded, the sponsor must be notified 
within [ADDRESS_903991] 
be recorded in the source d ocumentation and case report form (CRF) .
The study -specific I RT reference manual and I P manual will provide the contact [CONTACT_19974] s ystem.
6.4. Study Intervention Compliance
Compliance of single -blind placebo administr ation during the run-in period will be assessed 
by [CONTACT_21173][INVESTIGATOR_310767] 1(Visit 6) for the purpose of inclusion into the study .  Acceptable 
compliance will be defined as self -administration by  [CONTACT_669297]:
  90% of the study -supplied blinded placebo t aken by [CONTACT_669298]-in 
period (ie, V isit 4to Visit 5) -only 1dose is permitted to be missed .
Compliance of IPadministration will be assessed during the treatment phase of the study  by 
[CONTACT_669299] s returned by  [CONTACT_2416] s at Visits 7, 8, 9, 10, and 12.
>80% compliance with self -administration of the IPis expected from Day 1 (Visit 6) 
to Day 112(Visit 
12); investigators must closel y monitor non -compliant participants
in order to enhance their adherence to the stud y treat ment.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 38At Visit 4 (run- in), participants will be provided with a dosing diary  (or similar) and 
instructed on how to record each dose taken throughout the stud y through Visit 12 
(Week 16).  Participants will bring the dosing diary  to each clinic visit to be reviewed b y 
clinic staff.
6.5.
Concomitant Therapy
All concomitant medications taken during the study must be recorded with indication, daily 
dose, and start and stop dates of administration.  Attempts must be made to notalter the 
doses and regimens of chronic background medications after randomization and for the 
duration of participation in this study .  An y changes made to background medications must 
be communicated to the sponsor’s medical monitor as soon as practicall y possible ,and if 
agreed, be captured i n the CRF.  All participants must be questioned about concomitant 
medication at each outpatient visit to the clinical site . 
Medications taken before Visit 6(Day 1)will be documented as prior medication s.  
Medications taken after dosing of double -blind I P at Visit 6(Day  1) and until the second 
Follow -up (telephone contact [CONTACT_19383]) will be documented as concomitant medications.
Medications for Glycemic Control
Participants must be on a stable dose of metformin ( 500 mg /day) starting at  8weeks 
prior to Visit 1 (Screen 1) and until Visit 13 (on-site Follow -up).
The use of the following class esof agents is not permitted within 8weeks prior to 
Visit 1(Screen 1) and until Visit 13(on-site Follow-up):
Thiazolidinediones (TZDs )such as pi[INVESTIGATOR_669284]; 
Subcutaneously  administered agents for gl ycemic control (eg, insulin, exena tide, 
liraglutide, pramlintide);
Sodium -glucose co -transporter 2 inhibitors such as canagliflozin, dapagliflozin, 
empagliflozin ;
Sulfony lureas such as acetohexamide, c hlorpropamide, tolazamide, tolbutamine, 
glimepi[INVESTIGATOR_14956], glipi[INVESTIGATOR_7130], g lyburide ;
Meglitinide analogues such as repaglinide, nateglinide;
Dipeptidy l peptidase- 4 inhibitors (DPP -4i) such as sitagliptin, saxagliptin, linagliptin, 
vildagliptin; or
  glucosidase inhi bitors such as acarbose and miglitol.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 39Lipid -modify ing Medications
Useof background lipid -modify ing agent(s) are permitted unless otherwise specified in this 
protocol. If possible, d oses of 
lipid modify ing agents should be stable for 4weeks prior to 
Visit 1(Screen 1) and for the duration of the stud y.  Any changes to dose of lipid modify ing 
agents should be noted on the CRF.
Participants are permitted to be on stable doses of the following lipid-modify ing agents,
starting at  4 weeks prior to Visit 1 (Screen 1) and until Visit 13(on- site Follow-up), 
including (but not limited to) the following:
Statins such as atorvastatin, simvastatin, rosuvastatin, fluvastatin, pi[INVESTIGATOR_2830], and 
pravastatin;
Ezeti mibe .
The following lipid -modify ing agents are not per mitted in this study  within 4 weeks prior to 
Visit 1 (Screen 1) and for the duration of the stud y:
Bile acid sequestrants such as cholest yramine, colestipol , colesevalam ;
Fenofibrate and gemfobrozil;
Nicotinic acid/niacin; or
Monoclonal antibodies inhibiting proprotein convertase subtilisin/kexin ty pe 
9
(PCSK9 ),such as alirocumab andevolocumab .
Antihy pertensive Medications
Use of background antihy pertensive agent(s) is permitted unless otherwise specified in this 
protocol.  
For participants that enter the study  taking allowable antihy pertensive agents , doses should 
be stable for  4weeks prior to Visit 1 (Screen 1) and for the duration of the study .  An y 
changes to dose of blood pressure modify ing agents should be avoided if possible; however, 
if any  chan ges occur, they  must be noted on the CRF.
Other Acceptable Concomitant Medications
Any participant on the following list of medications must be on stable doses [ie, 8weeks
prior to Visit 1 (Screen 1) and until Visit 13 (on- site Follow- up), ifpossible ]:
Non-steroidal anti -inflammatory  drugs (NSAIDs) such as ibuprofen, ketoprofen, 
diclofenac, na proxen, indomethacin, meloxicam, and celecoxib.  I ntermittent use of 
these medications is also permitted;
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 40Intermittent use of acetaminophen/paracetamol at doses of up to 1 gram per day ;
Inhaled and topi[INVESTIGATOR_11930];
Thyroid replacement therapy and hormone replacement therap y (in eligible female s);
Anti- psychotic medications such as olanzapi[INVESTIGATOR_146617];
Antidepressant medications such as tricy clic agents ,selective serotonin reuptake 
inhibitors, and serotonin/norepi[INVESTIGATOR_5608];
Vitamin E, including high doses provided the regimen is stable;
Certain herbal supplements but only following consultation with sponsor;
Limited use of non- prescri ption medications that are not believed to affect subject 
safet y or the overall results of the study may be permitted on a case -by-case basis 
following approval b y the sponsor.
Other Prohibited Concomitant Medications
Participants must abstain from using t he following medications for 4weeks prior to 
Visit 1(Screen 1) and until Visit 13(on-site Follow-up):
Use of medications that are known OATP inhibitors including:
Rifampin, gemfibrozil, cy closporine, erythrom ycin and clarithrom ycin;
Chronic use of systemic glucocorticoids such as prednisone, dexamethasone, 
triamcinolone, budesonide, betamethasone; and immunosuppressants such as 
tacrolimus;
Pharmacological agents with approved indication for weight loss such as orlistat and 
sibutramine; 
Over -the-counte r appetite -simulant or appetite- suppressant, as advertised; 
(Medical -grade) marijuana, regardless of medical indication;
Specific classes of agents including :
Coumadin- type anticoagulants orother anticoagulants (eg, dabigatran); though
aspi[INVESTIGATOR_110247] ≤325 mg/day  is permitted;
Anticonvulsants; or
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 41Antiarrh ythmics , except for beta blockers if used for the management of 
conditions other than arrhy thmias (eg ,blood pressure control) ;
Medications h istorically  associated with fatt y liver are prohibited if used for 
4 week s ofcontinuous use in the previous 13months prior to Screen 1 (Visit 1), 
examples include : 
Amiodarone, methotrexate, tetracy clines, tamoxifen, estrogens at doses greater 
than those used for hormone replacement, anabolic steroids, valproic acid, or 
other known hepatotoxins.
6.5.1. Rescue Medic ine
There is no rescue therapy to reverse the AEs observed with PF-06835919; standard medical 
supportive care must be provided to manage the AEs. 
6.6.
Dose Modification
No dose modifications are permitted in this study .
6.7.Intervention A fter the End of the Study
No intervention will be provided to study participants at the end of the study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Inter vention
In rare instances, it may  be necessary  for a participant to permanentl y discontinue IP.  Also, 
it should be stressed that if the study  medication is discontinued for any  reason, it is fully  
anticipated that subjects continue in the study  per protoc ol (Off Drug In Study  or ODIS) per 
treatment policy  estimand.  Should the ODI S subject withdraw from the study , an Earl y 
Termination Visit should be scheduled at the time consent is withdrawn andevaluated for 
early termination procedures as listed in the SoA. 
ECG Changes 
A participant who meets either bulleted 
criteria based on the average of triplicate 
ECG readings will be withdrawn from the study . 
QTcF >500 msec;
Change from baseline (CFB) : QTc F>60 msec.
If a clinically signi ficant finding is identified (including, but not limited to, changes from 
baseline in QT cFafter enrollment ), the investigator or qualified designee will determine if 
the participant can continue in the study  and if any change in participant management is 
needed. This review of the ECG printed at the time of collection must be documented. Any 
new, clinicall y relevant finding should be reported as an AE.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 42See the SoA for data to be collected at the time of intervention discontinuati onand follow -up 
and for an y further evaluations that need to be completed.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request (and choose 
not to continue as an ODIS subject) or may  be withdrawn at an y time at the discretion of the 
investigator for safet y, behavioral, compliance, or administrative reasons.
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early  discontinuation visit applies only  to participants who are randomized and then are 
prematurel y withdrawn from the study.
  Participants should be questioned regarding their 
reason for withdrawal.   The participant will be permanently discontinued both from the study  
intervention and from the study  at that time.
If a participant withdr aws from the study , he/she may  request destruction of any  remaining 
samples, but data alread y generated from the samples will continue to be available, and may 
be used to protect the integrity  of existing anal yses.  The investigator must document any  
such requests in the site study  records.
If the participant withdraws from the study  and also withdraws consent (see below) for 
disclosure of future information, no further evaluations should be performed and no 
additional data should be collected.  The sponsor may retain and continue to use any  data 
collected before such withdrawal of consent.
When a 
participant withdraws from the study  because of an SAE, the SAE must be recorded 
on the CRF and reported on the Clinical Trial ( CT)SAE Report.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safet y was preserved.
Withdrawal of Consent: 
Participant s who request to discontinue receipt of study  treatment will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures.  The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
[CONTACT_78258].  Participant s should notify  the investigator in writing of the decision to 
withdraw consent from future follow- up, whenever possible.  The withdrawal of consent 
should be explained in detail in the medical records by  [CONTACT_093], as to whether the 
withdrawal is only  from further receipt of IPor also from study  procedures and/or 
posttreatment study  follow -up, and entered on the appropriate CRF page.  In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
PF-[ADDRESS_903992] be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_669300]/or 
should continue in the study ;
Before a participant is deemed los t to follow -up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record ;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study  as a whole ishandled as part of Appendix 1 .
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any  study -specific procedures.  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if t he participant should continue or discontinue study  
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be comp leted and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as a pplicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICD may be utilized for screening or baseline 
purposes provided the procedures met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 46section.  Identification of such incidental findings during the central review process should 
not be expected, and the site maintains responsibility  for performing a general safet y review 
of all images as per site protocols. 
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .  Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  concerns.
8.2.1. Physical Examinations
A complete ph ysical examination will occur at times specified in the SoA and include, at a 
minimum, assessments of the cardiovascular, respi[INVESTIGATOR_696] , 
gastrointestinal, and neurological
systems. Height 
(at Screen 1 only ) and weight will also be measured and recorded.
A limited physical examination will include, at a minimum, assessments of the skin, lungs, 
cardiovascular s ystem, and abdomen (liver and spleen) .
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses.
[IP_ADDRESS].
Measurement of Waist Circumference
As part of the ph ysical examination at Screen [ADDRESS_903993] 0.1 centimeter.  Measurement will be undertaken as follows:
While participant is in a standing po
sition with arms resting comfortabl y at the side;
Under standard conditions including post -void, with the tape touching the skin (not 
clothing);
At the end of a normal expi[INVESTIGATOR_1516] (when lungs are at their residual capacity ).
The measurement will consider th e following anatomical features as benchmarks:
Circumference of the narrowest part of the torso as viewed from the anterior aspect 
or;
If the narrowest part of the torso cannot be identified, the measurement must be made 
of the smallest horizontal circumf erence in the area between the ribs and the iliac 
crest.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 478.2.2. Body Weight
In this stud y, assessment of body weight will occur at the nominal time points specified in 
the SoA per the following specifications: 
Weight will be recorded usi ng a scale placed on a stable, flat surface;
Same scale, as much as practicall y possible , will be used with the scale reporting 
weight in kilograms or pounds, and accuracy  to the nearest 0.1 kg (or 0.2pounds ),ie, 
the device used for this study  must be able to distinguish a difference between 68.4 kg 
and 68.3 kg;
Measurement must be undertaken:
At approximately  the same time of the day  at each nominal time point;
After the participant has been asked to void (ie, forced void);
Under standard conditions (eg, participants must wear light clothing with content 
of their pockets emptied orhospi[INVESTIGATOR_669285]/jackets) .
8.2.3. Vital Signs
Pulse rate and BPwill be assessed in triplicate (2 -4 minutes between measurements) at times 
specified in the SoA section of this protocol per the following specifications:
At Screen 1 (Visit 1) only, the participant ’s arm circumference should be measured at 
the midpoint of the length of the upper arm using a flexibl e anthropometric tape to 
select the appropriate cuff to be used throughout the study  to measure BP/pulse rate 
via an automated device using an oscillometric method (not auscultation);
Participant s with arm circumference greater than the largest cuff size a vailable at 
each stud y site are not eligible.
Seated BP/pulse rate will be measured with the participant ’s arm supported at the 
level of the heart, and recorded to the nearest mmHg, following a rest of 5minutes ;
The s ame arm (preferably  the dominant arm) willbe used for BP/pulse rate 
assessment throughout the study ;
Participants
should be instructed nottospeak during BP/pulse rate measurements.
Additional collection times, or changes to collect ion times of BP/ pulse rate will be permitted, 
as necessary , to ensure appropriate collection of safet y data.
PF-[ADDRESS_903994] 12-l ead E CGs should be collected at times specified in the SoA section of this
protocol using an ECG machine that automatically calculates the heart rate and measures 
pulse rate , QT, and QTcF intervals and QRS complex .All scheduled ECGs should be 
performed after the participant has rested quietly  for 10minutes in a supi[INVESTIGATOR_2547]. 
If a postdose QTc Finterval remains ≥30msecfrom the baseline andis >450 msec; or an 
absolute QTc Fvalue is ≥500 msecfor any  scheduled ECG for greater than 4 hours (or 
sooner , at the discretion of the investigator), or QTc Fintervals get progressively  longer, the 
participant should under go continuous ECG monitoring.  A cardiologist should be consulted 
if QTc Fintervals do not return to less than the criterion listed above after 8 hours of 
monitoring (or sooner ,at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality.  It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read 
QTcFvalue is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.
8.2.5. Clinical Laboratory Assessments
See Appendix [ADDRESS_903995] an y 
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged b y the investigator to be more severe than expected for 
the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_903996] dose of stud y inter vention should be 
repeated until the values 
return to normal or baseline or are no longer considered clinically 
significant by [CONTACT_10982].
If such values do not return to normal/baseline within a period of time judged reasonable by
[CONTACT_093], the etiology  should be identified and the sponsor notified.
All protocol -required laboratory  assessments, as defined in Appendix 2, must be conducted 
in accordance with the laboratory  manual and the SoA.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 49If laboratory  values from non- protocol -specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in participant management or are considered 
clinically  significant b y the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.
[IP_ADDRESS]. Management of Glycemic Control
Hypoglycemic adverse events (HAEs) and fasting plasma glucose will be routinely  
monitored during participation in the study .
Based on this information , as well as review of the results reported b y the central laboratory, 
an assessment of an y symptomatic and asymptomatic occurrence of h ypo-or hyper-glycemia 
must be undertaken.
[IP_ADDRESS].1. Home Glucose Monitoring
To aide in management of their T2DM, all participants will be provided home 
glucose monitoring supplies including a sponsor -provided glucometer, instructions on 
the use of the glucometer and accompan ying supplies.
Home glucose monitoring logs will be provided to participants for completion at 
home and brought to each outpatient visit to the site along with the glucometers.
Investigators must review the home glucose monitoring logs completed by  [CONTACT_669301] -in visit (Visit 4 ).
Participants must perform home glucose monitoring at least [ADDRESS_903997] an 8 -(preferabl y 10-) hour fast (except water). However, the 
investigator may  recommend more frequent home glucose monitoring if needed.
Less frequent glucose monitoring will NOT be considered a protocol deviation unless 
the participant fails to monitor his/her glucose for 3 or more consecutive day s.
If the participant experiences s ymptoms of hy pogly cemia, home glucose monitoring 
should be performed, and these sy mptoms, along with the glucometer measurement, 
should be captured on the home glucose monitoring log.
If the participant uses his/her own glucometer, and not one provided b y the sponsor, a 
protocol deviation will NOT be recorded provided the investigator is still able to 
monitor the participant’s daily  glucose values according to the criteria stated above.
[IP_ADDRESS].2. Management of Hypoglycemia
Any epi[INVESTIGATOR_669286].
For the definition of a h ypogl ycemic epi[INVESTIGATOR_95461] y categorization see 
Section [IP_ADDRESS].2.[ADDRESS_903998] a fasting plasma glucose value (during home glucose monitoring) 
meeting the definition of hy poglycemia must be instructed to repeat the measurement the 
next day  (following at least an 8- (preferabl y 10-) hour fast, except water). If the second 
measurement also meets the below definition, participants must be asked to return to the site 
within 1 to 3 days (following at least an 8- (preferably 10 -) hour fast, except water) and have 
blood collected and sent to the central laboratory  for anal ysis of fasting plasma glucose.
[IP_ADDRESS].2.1. Definition and Severity of Categorization of Hypoglycemic Adverse Event 
(HAE)
Based on review of the participant completed home glucose monitoring log at each site visit, 
as well as results reported by  [CONTACT_2237] , the investigator must assess the glucose 
values as well as an y symptoms documented.
HAE is defined as 1of the following: 
1.Asymptomatic hypoglycemia: An event not accompanied by  [CONTACT_11017][INVESTIGATOR_107062] a plasma glucose value of <70 mg/dL (3.9 mmol/L) using glucometer (or 
sponsor -identified central laboratory );
2.Documented s ymptomatic hy poglycemia: An event during which t ypi[INVESTIGATOR_177253] a glucose value of <70 mg/dL (3.9 mmol/L) using 
glucometer (or sponsor -identified central laboratory ) and the clinical pi[INVESTIGATOR_177254], subcutaneous glucagon, or intrave nous (IV) 
glucose; 
3.Probable sy mptomatic hypogl ycemia: An event during which sy mptoms of HAE are 
not accompanied b y a plasma glucose determination but was presumabl y caused by a 
plasma glucose concentration of <70 mg/dL (3.9 mmol/L), and the clinical pi[INVESTIGATOR_669287], subcutaneous glucagon, or IV glucose.
Each epi[INVESTIGATOR_95465] y.In order to characterize 
the event as severe, all 3criteria below must be met:
1.The participant was una ble to treat him/herself. Neurologic impairment, and not the 
age of the participant, is the explanation for wh y the participant could not treat 
him/herself and required the assistance of another person.
2. The participant exhibited at least one of the follow ing neurological s ymptoms:
Memory  loss;
Confusion;
Uncontrolled behavior;
Irrational behavior;
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 51Unusual difficulty  in awakening;
Suspected seizure;
Seizure;
Loss of consciousness.
3.Either:
If blood glucose was measured and was ≤54mg/dL (2.7 mmol/L) using 
glucometer (or central laboratory ); or
If blood glucose was not measured, the clinical manifestations were reversed by  
[CONTACT_95489], subcutaneous glucagon, or intravenous glucose.
Events that do not meet all the criteria above for severe HAE are charac terized as mild or 
moderate in severity .
Any epi[INVESTIGATOR_95466].
[IP_ADDRESS].3. Management of Hyperglycemia
Hypergl ycemia is defined as the following:
Fasting plasma glucose ≥270 mg/dL (15.0 mmol/L) using glucometer (or central 
laboratory ). 
After randomization, participants noted to have a fasting plasma glucose value (during home 
glucose monitoring) meeting the above definition of hy pergl ycemia must be instructed to 
repeat the measurement the next day  (following at least an 8- (preferabl y10-) hour fast, 
except water). If the second measurement also meets the above definition, participants must 
be asked to return to the site a day  later (following at l east an 8 -(preferably 10-) hour fast, 
except water) and have blood collected for fasting plasma glucose (and shipped to the central 
laboratory  for anal ysis).
The investigator should determine if the participant collected the samples after an adequate 
fasting period; and if the participant is following recommended dietary  guidelines. Proper 
dietary  and collected procedures should be reinforced with the participant.
If the results from the central laboratory  confirm the readings using glucometer, the 
partic ipant should receive gl ycemic rescue medication at the discretion of the investigator 
(see Section 6.5.1).
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 528.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether it 
meets the criteria for classification as an S AE or that caused the participant to discontinue the
study (see Section 7). 
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -up 
information in an expedite d fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
For participant s who are screen failures, the active collection period ends when screen failure 
status is determined.
The time period for actively  eliciting and collecting AEs and S AEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving IP), through and including a minimum of 
28calendar day s, except as indicated below.
Medical occurrences that begin before the start of study  intervention but after obtaining 
informed consent will be recorded on the Medical History /Current Medical Conditio ns 
section of the CRF ,not the AE section.
Follow -up by  [CONTACT_74095] a level acceptable to the investigator, and 
[COMPANY_007] concurs with that assessment.
Investigators are not obligated to activel y seek AE sor SAE safter conclusion of the study  
participation .  However, if the investigator learns of an y SAE, including a death, at an y time 
after a participant has been discharged from the stu dy, and he/she considers the event to be 
reasonabl y related to the study  intervention or study  participation, the investigator must 
promptly  notify  the sponsor.
[IP_ADDRESS].
Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period are reported to [COMPANY_007] 
Safety  on the CT SAE Report Form i mmediatel y and under no circumstance should this 
exceed 24 hours, as indicated in Appendix 3 . The investigator will submit any  updated SAE 
data to the sponsor within 24 hours of it being available.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 53SAEs occurring in a participant after the active collection period has ended are reported to 
[COMPANY_007] Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at leas t a reasonable possibility  of being related to investigational 
product must be reported to [COMPANY_007] Safety .
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the CRF.
8.3.2. Method of Dete cting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bi as when detecting AEs and/or SAEs.  Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactiv ely follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Sa fety. 
Further information on follow -up procedures is given in Appendix 3 .
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation.   The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, institutional review boards (IRB s)/ethics committees 
(ECs
),and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R s) according to local regulatory requirements and sponsor policy  and 
forwarded to investigators as necessary .
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 54An investigator who rece ives an investigator safety report describing a nSAE or other 
specific safet y information (eg, summary or listing of SAEs) from the sponsor will review 
and then file it along with the investigator’s brochure and will notify  the IRB/EC, if 
appropriate accor ding to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the IPunder study  during pregnancy  or breastfeeding and occupational exposure 
are reportable to [COMPANY_007] Safet y within 24 hours of investigator awa reness.
[IP_ADDRESS]. Exposure During Pregnancy
Details of all pregnancies in female partners of male participants will be collected after the 
start of study  intervention and until [ADDRESS_903999] dose .
If a pregnancy  is reported, the investigator sh ould inform t he sponsor within 24 hours of 
learning of the pregnancy  and should follow the procedures outlined in Appendix 4 .
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pr egnancy ) are considered SAEs.
[IP_ADDRESS]. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to [COMPANY_007] Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE R eport Form.  An exposure during breastfeeding report is not created when a [COMPANY_007] 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwi se) gets in unplanned direct contact [CONTACT_8898], which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to [COMPANY_007] Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a participant enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file .
8.3.6. M edication Errors
Medication errors may  result from the administration or consumption of the IPby [CONTACT_181879] , or at the wrong time, or at the wrong dosage strength.
PF-[ADDRESS_904000] SAE Report 
Form to [COMPANY_007] Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors inc lude:
Medication errors involving participant exposure to the IP;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud y participant are t o be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determ ined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on an AE page of the 
CRF.
Medication errors should be reported to [COMPANY_007] Saf ety within [ADDRESS_904001] SAE Report 
Form only when associated with an SAE.
8.4.Treatment of Overdose
For this study , any  dose of PF -06835919 greater than 600 mg within a 24- hour time period 
will be considered an overdose.
Sponsor does not recommend spe cific treatment for an overdose .
Inthe event of an overdose, the investigator should:
1.Contact [CONTACT_669302] .
2.Closely  monitor the participant for an y AEs/SAE sand laboratory  abnormalities until 
PF-06835919 can no longer be detected s ystemicall y (at least 5 days).
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 60Estimand 1:
Estimand 1is intended to provide a population level estimate of the treatment effect of the 
IPalone relative to placebo under the scenario of no discontinuation of study  intervention, 
without the potential confounding effects of additional prohibited medications, regardles s of 
the participant’s compliance with the IP dosing.
Population: 
The target population consists of patients with NAFLD and T2DM on stable doses 
(500mg/day ) of metformin monotherapy .
Intercurrent Events: 
a.Withdrawal from study  intervention –All data co llected after a participant stops 
taking stud y medication will be excluded. 
b. Prohibited medications – All assessments after a participant receives prohibited 
medications that would modulate the primary  endpoints will be omitted from the 
analysis.  Receivin g a medication prohibited due to drug-
drug interaction ( DDI) risk 
will not affect this estimand.  The list of concomitant medications would be reviewed 
prior to database lock to determine which would be classed as “prohibited” for this 
estimand.
c.Inadequate compliance –Participants with inadequate compliance will have their 
primary  endpoint measurements used as recorded in the anal ysis.  
Population level summary : 
The population level summary  will be t he mean difference in change from baseline between 
PF-
[ADDRESS_904002].
Estimand 
2:
Estimand [ADDRESS_904003] to compliance or discontinuation of study  drug or administration of prohibited 
medication.   
Population: 
The target population consists of patients with NAFLD and T2DM on stable doses 
(500 mg/day ) of metformin monotherapy .
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 61Intercurrent Events: 
a.Withdr awal from study  intervention –All data collected regardless of a participant’s 
withdrawal from the study medication will be included in the anal ysis. 
b. Prohibited medications – A ll data collected for a participant regardless of the use of 
prohibited medic ations will be used in the anal ysis.
c.Inadequate compliance –Participants with inadequate compliance will have their 
primary  endpoint measurements used as recorded in the anal ysis. 
Population level summary : 
The population level summary  will be t he mean difference in change from baseline between 
PF-
[ADDRESS_904004].
9.2.Sample Size Determination
A sufficient number of participants will be screened to achieve approximately  
150participants randomly  assigned to IPand an e stimated total of 50 evaluable participants 
per intervention group.   A maximum of approximately 150 participants will be randomly  
assigned to IPsuch that approximately  132 evaluable participants complete the study .
This assumes 
an approximate 12% dropout rate resulting in [ADDRESS_904005] a 25 % mean reduction in whole liver fat from MRI -PDFF
compared to placebo is 98%using a [ADDRESS_904006] deviation (SD) of 0.36 in the log -scale (based 
on an internal stud y).  For the co- primary  endpoint of HbA1c , the power to detect a 
0.75% mean reduction compared to placebo is 96% using a [ADDRESS_904007] and a 2- sided 
Type I error rate of 0.1 assuming a pooled SD of 1%.  There will not be any  adjustment for 
multiplicity  in the assessment of hy potheses for the 2 co- primary  endpoints.
The number of participants in the sub -study  will be recruited based on feasibility .
9.3.Populations for Analysi s
For purposes of analy sis, the following populations are defined:
Population Description
Pre-randomization All participants entering the placebo run -in phase .
Randomly  assigned to 
TreatmentDefined according to Full Analy sis Set .
Safety All participan ts randomly  assigned to treatment and who 
take at least 1 dose of treatment.  Participants will be 
analyzed according to the dose they  actually  received.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 6610. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducte d in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines;
Applicable International Council for Harmonisation (I CH) Good Clinical Practice 
(GCP) g uidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, investigator’s brochure ( I B), and oth er relevant 
documents (eg, advertisements) must be reviewed and approved by  [CONTACT_177269] I RB/EC by  [CONTACT_20003] b y the IRB/EC 
before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of t he study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversi ght of the conduct of the stud y at the site and adherence to 
requirements of 21 Code of Federal Regulations ( CFR ), ICH guidelines, the I RB/EC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Brea ches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, [COMPANY_007] should be informed immediately. 
PF-[ADDRESS_904008], and 
of an y serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of.
10.1.2.
Financial Disclosure
Investigators and subinvestigators will provide the sponsor with s ufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 yearafter completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorized representative and answer all questions regarding the 
study .
Participants must be informed that their participation is voluntary .Participants or their 
legally  authorized representative will be required to sign a statement of informed consent that 
meets th e requirements of [ADDRESS_904009] (HIPAA) requirements, where applicable, and the 
IRB/EC or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of data related to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records m ay be examined by  [CONTACT_160439], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the p articipant was enrolled in the study  and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the IC D
.
Participants must be reconsented to the most current version of the IC D(s) during their 
partic ipation in the study .
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 68A cop y of the IC D(s) must be provided to the participant or the participant’s legall y 
authorized representative.
Participants who are rescreened are required to sign a new IC D.
The I CDwill contain a separate section that addresses th e use of remaining mandatory  
samples for optional exploratory  research. The investigator or authorized designee will 
explain to each participant the objectives of the exploratory  research. Participants will be 
told that they  are free to refuse to partici pate and may  withdraw their consent at any  time and 
for an y reason during the storage period. A separate signature [CONTACT_22862] a 
participant's agreement to allow an y remaining specimens to be used for exploratory 
research. Participants w ho decline to participate in this optional research will not p rovide 
this separate signature .
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure p rotection of participant data.
Participants’ personal data will be stored at the study  site in encrypted electronic and/or paper 
form and will be password protec ted or secured in a locked room to ensure that only  
authorized study  staff have access.  The st udy site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study  site shall be responsible 
for determining whe ther a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data, participants will be assigned a single, participant -specific numerical code.
Any participant records or data sets that are transferred to the sponsor will contain the 
numerical code; participant names will not be transferred. All other identifiable data 
transferred to the sponsor will be identif ied by  [CONTACT_20007], participant -specific code. The 
study  site will maintain a confidential list of participant s who participated in the study , 
linking each participant ’s numerical code to his or her actual identity . In case of data 
transfer, the sponsor will protect the confidentiality  of participants’ personal data consistent 
with the c linical study agreement and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results throug h posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.  I n addition, [COMPANY_007] reports stud y results outside of the 
requirements of local laws/regulations pursuant to its s tandard operating procedures (SOPs).
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported r egardless of the outcome of the study  or the country  in 
which the study  was conducted.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 69www.clinicaltrials.gov
[COMPANY_007] posts clinical trial US Basic Results on www.clinicaltrials.gov for [COMPANY_007] -sponsored 
interventional studies (conducted in patients) that ev aluate the safet y and/or efficacy of a 
product, regardless of the geographical location in which the study is conducted.  US Basic 
Results are generall y submitted for posting within 1 year of the primary completion date 
(PCD) for studies in adult populations or within [ADDRESS_904010]
[COMPANY_007] posts European Union (EU) Basic Results on EudraCT for all [COMPANY_007] -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitt ed 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identi fy individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the European Medicines Agency  (EMA) website.  Clinical data, under Phase 1 of this 
policy , includes clinical overviews, clinical summaries, CSRs, and appendice s containing the 
protocol and protocol amendments, sample CRFs, and statistical methods.  Clinical data, 
under Phase 2 of this policy , includes the publishing of individual participant data.  Policy  
0070 applies to new marketing authorization applications submitted via the centralized 
procedure since 01 January 2015 and applications for line extensions and for new indications 
submitted via the centralized procedure since 01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient- level d ata or full CSRs for the purposes 
of “bona -fide scientific research” that contribute to the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations.  CSRs will have personall y identifiable information 
redacted.
PF-[ADDRESS_904011], including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and c orrect by  [CONTACT_20010].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are secure ly stored at the study site i n encr ypted 
electronic and/or paper form and are password protec ted or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -
related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.   This 
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspecti ons and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk
-based initiatives in operations and quality  
such as risk management and mitigation strategies and analytical r isk-based monitoring), 
methods, responsibilities ,and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring) ,are provided in the 
monitoring plan.
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and right s of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for [ADDRESS_904012] ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 71When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify thesponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study .  Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records.  The investigator will promptly  
provide copi[INVESTIGATOR_19946].  Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Source Documents
Source documents prov ide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source document s are filed at the investigator site.
Data reported on the CRF or entered in the electronic CRF ( eCRF )that are transcribed from 
source documents must be consistent with the source documents or the discrepancies must be 
explained . The investigator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be available.
Definition of what constitutes source data can be found in the study  monitoring plan .
10.1.8. Study and Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponso r.Study  sites will be closed upon 
study  completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the contract 
research organization ( CRO )if requested to do so by  [CONTACT_22846]/EC or if such 
termination is required to protect the health of study participants .
Reasons for the earl y closure of a stud y site b y the s ponsor may  include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitment of participants by  [CONTACT_093] ;
Discontinuation of further study  intervention development .
Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights .
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 7210.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after end of the study  (or 
study  termination), whichever comes first. 
The inve stigator agrees to refer to the primary  publication in any  subsequent publications 
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, remove an y previously  undisclosed 
confidential information before disclosure, except for an y stud y-or [COMPANY_007] 
intervention -related information necessary  forthe appropriate scientific presenta tion or 
understanding of the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_669303].
The sponsor will comply  with the requirements for publication of the over all study  results 
covering all i nvestigator sites.   In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicent er studies only  in their entirety and not as 
individual site data.  In this case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publications for the overall study  results will be determined by  [CONTACT_669304] e with I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contac t information for the sponsor's appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_78276] (SToD) 
system.  
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, participant s are provided with a contact [CONTACT_1137].  The contact [CONTACT_95504], at a minimum, protocol and investigational product identifiers, participant numbers, 
contact [CONTACT_22850], and contac t details for a contact [CONTACT_74072] a medical 
question or problem originating from another healthcare professional not involved in the 
participant ’s participation in the study .  The contact [CONTACT_74073]; however, it should be used 
only in the event that the established communication pathway s between the investigator site 
and the study  team are not available.  It is therefore intended to augment, but not replace, the 
established communication pathway s between the investigator site and the study  team for 
PF-[ADDRESS_904013] 
number is not intended for use b y the participant directly , and if a participant calls that 
number, he or she will be directed back to the investigator site.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 75Laboratory  results that could unblind the study  will not be reported to investigator sites or 
other blinded personnel unt il the study  has been unblinded are as follows: HbA1c, insulin, 
hs-CRP, uric acid, and GGT.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 80The investigator will use clinical judgment to determine the re lationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other risk 
factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will al so consult the investigator’s brochure (IB) and/or p roduct 
i
nformation, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to the sponsor .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  assessment.
The causality  asse ssment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the investigational product caused 
the event, then the event will be handled as “related to investigational product” for
reporting purposes, as defined by  [CONTACT_456] .  In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator must 
record this causal relationship in the source documents and CRF, and report such an 
assessme nt in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 8310.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they agree to the following requirements during 
the intervention period and for at least 5daysafter the last dose of stud y intervention, which
corresponds to the time needed to eliminate study  intervention(s) :
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent .
OR
Must agree to use a male condom when engaging in a ny activity  that allows for 
passage of ejaculate to another person .
I
naddition to male condom use, a highl y effective method of contraception is 
required for WOCBP partners of male participants (refer to the list of highly  effective 
methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she i s not a WOCBP (see definitions 
below in Section 10.4.3).
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Document ed hysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 84For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discre tion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview.   The method of documen tation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female:
A postmenopausal state is defined as age 60 years or older or no menses for 
12months without an alternative medical cause. 
A high follicle -
stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormone replacement therap y (HRT). 
Females on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highl y effective contraception methods 
if they  wish to continue their HRT during the study .  Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contracepti onMethods
Highly Effective Methods
The following appl y to WOCBP partners of male participants:
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device (IUD) .
3.Intrauterine hormone -releasing s ystem (IUS) .
4.Bilateral t ubal occlusion.
5.Vasectomized partner :
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed.  If not, an addit ional highly  effective method 
of contraception should be used.  The spermatogenesis cy cle is approximately  
90days.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 856.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation :
Oral;
Intravaginal;
Transder mal;
Injectable .
7.Progestogen -only hormone contraception associated with inhibition of ovulation :
Oral;
Injectable .
8.Sexual abstinence :
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.   The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.
Collection of Pregnancy Info rmation
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact 
[CONTACT_4490] a [COMPANY_007] product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the tim e of conception and/or is exposed 
during his partner’s pregnancy .
If a participant ’s partner becomes or is found to be pregnant during the participant ’s 
treatment with the investigational product, the investigator must report this information to 
[COMPANY_007] Saf ety on the CT SAE Report Form and an EDP supplemental form, regardless of 
whether an SAE has occurred.
  In addition, the investigator must submit information 
PF-[ADDRESS_904014] be done irrespective of whether an AE has 
occurred and within 24 hours of awareness of the exposure.  The information submitted 
should include the anticipated date of delivery  (see below for information related to 
termin ation of pregnancy).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination sho uld be specified and, if clinically possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
If the o utcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death ]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to [COMPANY_007] Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that o ccur within [ADDRESS_904015]. 
Additional information regarding the EDP may  be requested by  [CONTACT_456].  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must document in the source documents that 
the participant was given the Pregnant Partne r Release of Information Form to provide to his 
partner.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 8810.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some participant s, transaminase elevations are a harbin ger of a 
more serious potential outcome.  These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as drug -induced 
liver injury  (DILI).  Participant s who experience a transaminase elevat ion above 3 times the 
upper limit of normal ( ×ULN) should be monitored more frequentl y to determine if they  are 
an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  [CONTACT_74097].  The increase in TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same lab oratory
sample).  In rare instances, by  [CONTACT_22858], AST/AL T values might 
have decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteri a outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalit ies for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions.  Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above th e ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased fro m 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
PF-[ADDRESS_904016]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_904017] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, creatine kinase (CK), direct and 
indirect bilirubin, gamma -glutam yl transferase (GGT), prothrombin time (PT)/international 
normalized ratio (INR), total bile acids, and alkaline phosphatase.  Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology .  A detailed history , including relevant 
information, such as review o f ethanol, acetaminophen (either b y itself or as a coformulated 
product in prescription or over -the-counter medications) , recreational drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a 
jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected.  Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  tract ) and collection of 
serum sample for acetaminophen drug and/or protein adduct levels may  be warranted.
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential D ILI (H y’s law) cases if no 
other reason for the liver function test ( LFT)abnormalities has y et been found.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability 
of all the results of the investigations performed to determine etiology of the LFT 
abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
PF-[ADDRESS_904018] clinical trial
CTA clinical trial application
CTCAE Common Terminology Criteria for Adverse Events
CYP450 cytochrome P450
dB/m decibels per meter
DCT data collection tool
DDI drug-drug interaction
DILI drug-induced liver injury
dL deciliter
DMC data monitoring committee
DPP-4i dipeptidyl peptidase-4 inhibitors
DU dispensable unit
EC50 50% of the maximum effect
EC ethics committee
ECG electrocardiogram
e-CRF electronic case report form
E-DMC external data monitoring committee 
EDP exposure during pregnancy
EFD embryo-fetal development
Emax efficacy
EU European Union
EudraCT European Clinical Trials Database
F1P fructose-1-phosphate
F bioavailability
FIH first in human
FSH follicle-stimulating hormone
fu unbound plasma fraction
F/U Follow-up
GCP Good Clinical Practice
GFR glomerular filtration rate
GGT gamma-glutamyl transferase
GLP Good Laboratory Practice
GLP-1r glucagon-like peptide 1 receptor
HAE(s) hypoglycemia adverse event(s)
HbA1c hemoglobin A1C
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCC hepatic cellular carcinoma
HCV hepatitis C virus
HCVAb hepatitis C antibody
HDL-C high-density lipoprotein cholesterolCCI
PF-[ADDRESS_904019]
HIV human immunodeficiency virus
HOMA- IR homeostatic model assessment of insulin resistance
hs-CRP high-sensitivity  C-reactive protein
IB Investigator’s Brochure
IC50 50% of the inhibition con centration
ICD informed consent document
ICH International C ouncil for Harmonisation
ID identification
IDL intermediate -densit y lipoprotein
IL-[ADDRESS_904020] modification of diet in renal disease
MEL D model of end- stage liver disease
mg milligram
min minute
mL milliliter
mmHg millimeters of mercury
mmol/L millimoles per liter
MMRM mixed model with repeated measures
MOA mechanism of action
MRI magnetic resonance imaging
msec millisecond
N/A not applicable
NAFLD nonalcoholic fatt y liver disease
NASH nonalcoholic steatohepatitis
ND not determined
ng nanograms
NOAEL no observed adverse effect level
NOEL no observed effect level
NIMP non investigational medicinal product
NSAID non-steroidal anti -inflammatory drugs
NYHA [LOCATION_001] Heart Association
OAT organic anion- transporter
OATP organic anion- transporting pol ypeptide
OMI M Online Mendelian Inheritance in Man
PACL protocol a dministrative change letter
PCD primary  completion date
PCSK9 proprotein convertase subtilisin/kexin ty pe 9
PD pharmacod ynamic(s)
PDE phosphodiesterase
PDFF proton density  fat fraction
P-gp P-glycoprotein
PGx pharmacogenomic(s)
PI [INVESTIGATOR_669288]/L pi[INVESTIGATOR_669289] y
QRS pulses in a heart beat
QT Q wave to end of T wave
QTc QT corrected
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 96Abbreviation Term
QTcF QTc corrected by [CONTACT_6550]'s formula
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
SD standard deviation
SEM standard error of the mean
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SoA schedule of activities
SOP standard operating procedure
SPF sun protection factor
SRSD single reference safety document
SSID study-specific subject identification number
S[LOCATION_003]R suspected unexpected serious adverse reaction
t½ terminal half-life
T2DM Type [ADDRESS_904021] upper limit of normal
US [LOCATION_002]
UV ultraviolet
V visit
VLDL very low-density lipoprotein
VCTE vibration controlled transient elastography
VS vital signs
Vss volume of distribution
WBC white blood cells
WOCBP women of childbearing potentialCCI
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 9711.REFERENCES
1. Online Mendelian Inheritance in Man, OMIM. Johns Hopkins University , Baltimore, 
MD. MI M Number: {229800}: {June 20 16}: World Wide Web URL : http://omim.org/.
2. Sachs B, Sternfeld L, Kraus G. Essential fructosuria: I ts pathophy siology . Am J Dis 
Child 1942; 63:252 - 69.
3. Boesiger P, Buchli R, Meier D, et al.  Changes of liver metabolite concentrations in 
adults with disorders of fructose metabolism after intravenous fructose by  31P ma gnetic 
resonance spectroscop y. Pediatr Res 1994;4:436-40.
4. Abdelmalek MF, Lazo M, Horska A, et al. Fatt y Liver Subgroup of Look, A. R. G., 
Higher dietary  fructose is associated with impaired hepatic adenosine triphosphate 
homeostasis in obese individuals with ty pe 2 diabetes. Hepatology  2012;56:952 -60.
5. Maenpaa PH, Raivio KO, Kekomaki MP. L iver adenine nucleotides: fructose -induced 
depletion and its effect on protein sy nthesis. Science 1968;161:1253 -4.
6. Lanaspa MA, Sanchez -Lozada L G, Choi YJ, et al. 
Uric acid induces hepatic steatosis by  
[CONTACT_669305]: potential role in fructose -dependent and 
-independent fatty liver. J Biol Chem 2012;287:[ZIP_CODE]-44.
7. Erion DM, Popov V, Hsiao JJ, et al. The role of the carboh ydrate response 
element -binding protein in male fructose -fed rats. Endocrinology  2013;154:36 -44.
8. Softic S, Cohen DE, Kahn CR. Role of dietary  fructose and hepatic de novo lipogenesis 
in fatty  liver disease. Dig Dis Sci 2016;61:1282-93.
9. Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose -sweetened, not 
glucose -sweetened, beverages increases visceral adiposity  and lipi[INVESTIGATOR_669290]/obese humans. J Clin I nvest 2009;119:1322-34.
10. Abid A, Taha O, Nseir W, et al. Soft drink consumption is associated with fatty  liver 
disease independent of metabolic sy ndrome. J Hepatol 2009;51:918-24.
11. Assy  N, Nasser G, Kamay se I, et al. Soft drink consumption linked with fatty  liver in 
the absence of traditional risk factors. Can J Gastroenterol 2008;22:[ADDRESS_904022] of a high -fructose weight -
maintaining diet on lipogenesis and liver fat. J Clin Endocrinol Metab 
2015;100:2434-42.
13. Lustig R, M ulligan K, Noworolski SM, et al. I socaloric fructose restriction and 
metabolic improvement in children with obesity  and metabolic sy ndrome. Obesity  
2016;24:453 -60.
PF-06835919
Protocol C1061011
Final Protocol Amendment 2, 11 September 2019
PFIZER CONFIDENTIAL
Page 9814. Stanhope KL, Medici V, Bremer AA, et al. A dose -response stud y of consuming high -
fructose co rn syrup-sweetened beverages on lipid/lipoprotein risk factors for 
cardiovascular disease in y oung adults. Am J Clin Nutr 2015;101:1144-54.
15. Sany al AJ, Friedman SL , McCullough AJ, et al. American Association for the Study  of 
Liver Diseases, [LOCATION_002] Fo od and Drug Administration. Challenges and 
opportunities in drug and biomarker development for nonalcoholic steatohepatitis: 
findings and recommendations from an American Association for the Study of L iver 
Diseases -U.S. Food and Drug Administration Joint W orkshop. Hepatology 2015; 
61:1392-05.
16. Ishimoto T, Lanaspa MA, L e MT, et al. Opposing effects of fructokinase C and A 
isoforms on fructose -induced metabolic s yndrome in mice. Proc Natl Acad Sci [LOCATION_003] 
2012;109:4320-5.
17. Le TA, Chen J, Chanqchien C, et al.  Effec t of colesevelam on liver fat quantified by  
[CONTACT_110295]: a randomized controlled trial. 
Hepatology  2012;56:922-32.  
18. Loomba R, Sirlin CB, Ang B, et al.  Ezetimibe for the treatment of nonalcoholic 
steatohepatitis: assessment by  [CONTACT_110296] y in a randomized trial (MOZART Trial). Hepatology 
2015;61:1239-50.
19. Stanhope KL, Schwarz JM, Keim NL et al.  Consuming fructose -sweetened, not 
glucose -sweetened, beverages increa ses visceral adiposity  and lipi[INVESTIGATOR_669290]/obese humans. J Clin I nvest 2009;119 (5):1322 -34.